
|Articles|July 1, 2002
Modified steroid has 'potential' for treating subfoveal CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sight Sciences reports new data supporting long-term efficacy of OMNI Surgical System
2
Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression
3
Retina experts reflect on how OCT transformed patient care
4
When policy meets parenthood: Examining residency leave in ophthalmology
5



















































.png)


